{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T14:38:53Z","timestamp":1759588733465},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1007\/s11906-008-0041-y","type":"journal-article","created":{"date-parts":[[2008,10,9]],"date-time":"2008-10-09T23:17:25Z","timestamp":1223594245000},"page":"216-221","source":"Crossref","is-referenced-by-count":12,"title":["Mineralocorticoid antagonism and cardiac hypertrophy"],"prefix":"10.1007","volume":"10","author":[{"given":"Kohzo","family":"Nagata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,10,10]]},"reference":[{"key":"41_CR1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.amjcard.2005.10.017","volume":"97","author":"T. Amano","year":"2006","unstructured":"Amano T, Matsubara T, Izawa H, et al.: Impact of plasma aldosterone levels for prediction of in-stent restenosis. Am J Cardiol 2006, 97:785\u2013788.","journal-title":"Am J Cardiol"},{"key":"41_CR2","doi-asserted-by":"crossref","first-page":"H2710","DOI":"10.1152\/ajpheart.01399.2006","volume":"293","author":"T. Muto","year":"2007","unstructured":"Muto T, Ueda N, Opthof T, et al.: Aldosterone modulates I(f) current through gene expression in cultured neonatal rat ventricular myocytes. Am J Physiol Heart Circ Physiol 2007, 293:H2710\u2013H2718.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"41_CR3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10557-006-8282-y","volume":"20","author":"T.D. Szucs","year":"2006","unstructured":"Szucs TD, Holm MV, Schwenkglenks M, et al.: Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction\u2014an analysis of the EPHESUS study from a Swiss perspective. Cardiovasc Drugs Ther 2006, 20:193\u2013204.","journal-title":"Cardiovasc Drugs Ther"},{"key":"41_CR4","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/00004872-200405000-00001","volume":"22","author":"N.M. Kaplan","year":"2004","unstructured":"Kaplan NM: The current epidemic of primary aldosteronism: causes and consequences. J Hypertens 2004, 22:863\u2013869.","journal-title":"J Hypertens"},{"key":"41_CR5","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/HYPERTENSIONAHA.107.095448","volume":"50","author":"C. Catena","year":"2007","unstructured":"Catena C, Colussi G, Lapenna R, et al.: Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007, 50:911\u2013918.","journal-title":"Hypertension"},{"key":"41_CR6","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/01.HYP.0000203732.03784.3b","volume":"47","author":"J.W. Funder","year":"2006","unstructured":"Funder JW: Mineralocorticoid receptors and cardiovascular damage: it\u2019s not just aldosterone. Hypertension 2006, 47:634\u2013635.","journal-title":"Hypertension"},{"key":"41_CR7","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.tem.2005.02.010","volume":"16","author":"G. Rossi","year":"2005","unstructured":"Rossi G, Boscaro M, Ronconi V, Funder JW: Aldosterone as a cardiovascular risk factor. Trends Endocrinol Metab 2005, 16:104\u2013107.","journal-title":"Trends Endocrinol Metab"},{"key":"41_CR8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.amjhyper.2005.05.013","volume":"19","author":"K. Matsumura","year":"2006","unstructured":"Matsumura K, Fujii K, Oniki H, et al.: Role of aldosterone in left ventricular hypertrophy in hypertension. Am J Hypertens 2006, 19:13\u201318.","journal-title":"Am J Hypertens"},{"key":"41_CR9","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","volume":"45","author":"P. Milliez","year":"2005","unstructured":"Milliez P, Girerd X, Plouin PF, et al.: Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005, 45:1243\u20131248.","journal-title":"J Am Coll Cardiol"},{"key":"41_CR10","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1001\/jama.295.22.2638","volume":"295","author":"L.A. Sechi","year":"2006","unstructured":"Sechi LA, Novello M, Lapenna R, et al.: Long-term renal outcomes in patients with primary aldosteronism. JAMA 2006, 295:2638\u20132645.","journal-title":"JAMA"},{"key":"41_CR11","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1161\/01.CIR.0000153800.09920.40","volume":"111","author":"G.M. Kuster","year":"2005","unstructured":"Kuster GM, Kotlyar E, Rude MK, et al.: Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation 2005, 111:420\u2013427.","journal-title":"Circulation"},{"key":"41_CR12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1291\/hypres.29.211","volume":"29","author":"A. Sato","year":"2006","unstructured":"Sato A, Saruta T, Funder JW: Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection. Hypertens Res 2006, 29:211\u2013216.","journal-title":"Hypertens Res"},{"key":"41_CR13","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1161\/CIRCULATIONAHA.105.571653","volume":"112","author":"H. Izawa","year":"2005","unstructured":"Izawa H, Murohara T, Nagata K, et al.: Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation 2005, 112:2940\u20132945.","journal-title":"Circulation"},{"key":"41_CR14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jsbmb.2004.12.010","volume":"93","author":"J.W. Funder","year":"2005","unstructured":"Funder JW: RALES, EPHESUS and redox. J Steroid Biochem Mol Biol 2005, 93:121\u2013125.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"41_CR15","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1161\/01.HYP.0000203772.78696.67","volume":"47","author":"K. Nagata","year":"2006","unstructured":"Nagata K, Obata K, Xu J, et al.: Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 2006, 47:656\u2013664.","journal-title":"Hypertension"},{"key":"41_CR16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/ncpendmet0016","volume":"1","author":"J.W. Funder","year":"2005","unstructured":"Funder JW: Mineralocorticoid-receptor blockade, hypertension and heart failure. Nat Clin Pract Endocrinol Metab 2005, 1:4\u20135.","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"41_CR17","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.cardfail.2004.03.002","volume":"10","author":"M.P. Okoshi","year":"2004","unstructured":"Okoshi MP, Yan X, Okoshi K, et al.: Aldosterone directly stimulates cardiac myocyte hypertrophy. J Card Fail 2004, 10:511\u2013518.","journal-title":"J Card Fail"},{"key":"41_CR18","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1210\/en.2005-1244","volume":"147","author":"M. Yamamuro","year":"2006","unstructured":"Yamamuro M, Yoshimura M, Nakayama M, et al.: Direct effects of aldosterone on cardiomyocytes in the presence of normal and elevated extracellular sodium. Endocrinology 2006, 147:1314\u20131321.","journal-title":"Endocrinology"},{"key":"41_CR19","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1161\/CIRCULATIONAHA.104.503706","volume":"111","author":"A. Ouvrard-Pascaud","year":"2005","unstructured":"Ouvrard-Pascaud A, Sainte-Marie Y, B\u00e9nitah JP, et al.: Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 2005, 111:3025\u20133033.","journal-title":"Circulation"},{"key":"41_CR20","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.yjmcc.2003.12.004","volume":"36","author":"M.S. Ahmed","year":"2004","unstructured":"Ahmed MS, \u00d8ie E, Vinge LE, et al.: Connective tissue growth factor\u2014a novel mediator of angiotensin II-stimulated cardiac fibroblast activation in heart failure in rats. J Mol Cell Cardiol 2004, 36:393\u2013404.","journal-title":"J Mol Cell Cardiol"},{"key":"41_CR21","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.yjmcc.2004.04.022","volume":"37","author":"T.J. Kemp","year":"2004","unstructured":"Kemp TJ, Aggeli IK, Sugden PH, Clerk A: Phenylephrine and endothelin-1 upregulate connective tissue growth factor in neonatal rat cardiac myocytes. J Mol Cell Cardiol 2004, 37:603\u2013606.","journal-title":"J Mol Cell Cardiol"},{"key":"41_CR22","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/01.mnh.0000133976.32559.b0","volume":"13","author":"F.J. Frey","year":"2004","unstructured":"Frey FJ, Odermatt A, Frey BM: Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension. Curr Opin Nephrol Hypertens 2004, 13:451\u2013458.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"41_CR23","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1161\/CIRCULATIONAHA.106.653964","volume":"115","author":"G. G\u00fcder","year":"2007","unstructured":"G\u00fcder G, Bauersachs J, Frantz S, et al.: Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 2007, 115:1754\u20131761.","journal-title":"Circulation"},{"key":"41_CR24","doi-asserted-by":"crossref","first-page":"R946","DOI":"10.1152\/ajpregu.00402.2006","volume":"292","author":"T. Ohtani","year":"2007","unstructured":"Ohtani T, Ohta M, Yamamoto K, et al.: Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: beneficial effects of mineralocorticoid receptor blocker. Am J Physiol Regul Integr Comp Physiol 2007, 292:R946\u2013R954.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"41_CR25","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1161\/HYPERTENSIONAHA.107.091058","volume":"50","author":"M. Nagase","year":"2007","unstructured":"Nagase M, Matsui H, Shibata S, et al.: Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension 2007, 50:877\u2013883.","journal-title":"Hypertension"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-008-0041-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-008-0041-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-008-0041-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:14:21Z","timestamp":1559434461000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-008-0041-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["41"],"URL":"https:\/\/doi.org\/10.1007\/s11906-008-0041-y","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}